Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Pharmacokinetic (PK) Clinical Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in Comparison with Epinephrine Administered as an Injection for Anaphylaxis Treatment

Next Previous
Trial Profile

A Pivotal Pharmacokinetic (PK) Clinical Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in Comparison with Epinephrine Administered as an Injection for Anaphylaxis Treatment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AQST 108 (Primary) ; Epinephrine; Epinephrine
  • Indications Anaphylaxis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Aquestive Therapeutics

Most Recent Events

  • 25 Oct 2024 According to an Aquestive Therapeutics media release, a subsequent analysis of the data from this pivotal study will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which is being held from October 24-28 in Boston, Massachusetts.
  • 21 Feb 2023 According to an Aquestive Therapeutics media release, data from this trial will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting 2023.
  • 25 Mar 2021 According to an Aquestive Therapeutics media release, the company plans on meeting with the FDA in the second half of 2021 to review these results and discuss next steps in the development of AQST-108.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top